Cargando…

OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver diseases in the United States. Simple and benign steatosis can gradually develop into the more serious conditions of nonalcoholic steatohepatitis (NASH) and cirrhosis. Population studies have demonstrated that men and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Qianying, Arredondo Eve, Alicia, Chen, Karen L, Smith, Brandi, Kulkoyluoglu-Cotul, Eylem, Wrobel, Kinga, Zhao, Yiru C, Hieronymi, Kadriye, Kim, Sung Hoon, Katzenellenbogen, Benita, Katzenellenbogen, John, Madak Erdogan, Zeynep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554909/
http://dx.doi.org/10.1210/js.2019-OR09-2
_version_ 1783425048038604800
author Zuo, Qianying
Arredondo Eve, Alicia
Chen, Karen L
Smith, Brandi
Kulkoyluoglu-Cotul, Eylem
Wrobel, Kinga
Zhao, Yiru C
Hieronymi, Kadriye
Kim, Sung Hoon
Katzenellenbogen, Benita
Katzenellenbogen, John
Madak Erdogan, Zeynep
author_facet Zuo, Qianying
Arredondo Eve, Alicia
Chen, Karen L
Smith, Brandi
Kulkoyluoglu-Cotul, Eylem
Wrobel, Kinga
Zhao, Yiru C
Hieronymi, Kadriye
Kim, Sung Hoon
Katzenellenbogen, Benita
Katzenellenbogen, John
Madak Erdogan, Zeynep
author_sort Zuo, Qianying
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver diseases in the United States. Simple and benign steatosis can gradually develop into the more serious conditions of nonalcoholic steatohepatitis (NASH) and cirrhosis. Population studies have demonstrated that men and postmenopausal women have higher incidences of NAFLD compared to premenopausal women, suggesting a protective role for estrogens. The decrease in estrogens due to the onset of menopause make postmenopausal women more susceptible to weight gain, fat redistribution to abdominal areas, dyslipidemia, hypertension and insulin resistance, all of which are major hallmarks of metabolic syndrome and are associated with NAFLD. Pathway preferential estrogen 1 (PaPE-1) is a novel estrogen receptor ligand that has been shown to favorably affect metabolic tissues without stimulating reproductive tissues. Though its effects on weight gain and fat accumulation have been previously investigated, its effects on liver transcriptome and plasma metabolites have yet to be determined. We use transcriptomics and metabolomics analysis to characterize the effects of PaPEs in two different mouse models: diet-induced obesity (DIO) and leptin-deficient (ob/ob) mice. PaPE-1 significantly decreased liver weight and lipid accumulation in both DIO and ob/ob models. Integrated pathway analysis using transcriptomics and metabolomics data showed that PaPE-1 treatment lowered genes associated with inflammation, collagen deposition, and fatty acid metabolism. On the other hand, PaPE-1 significantly increased expression of mitochondrial genes, particularly ones associated with electron transport chain and ribosome synthesis suggesting an increase in energy expenditure and mTOR signaling activity. In addition, PaPE-1 treatment restored insulin sensitivity in hepatocytes. Overall, our data show that PaPE-1 provides a metabolic benefit without stimulation of reproductive tissues.
format Online
Article
Text
id pubmed-6554909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65549092019-06-13 OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets Zuo, Qianying Arredondo Eve, Alicia Chen, Karen L Smith, Brandi Kulkoyluoglu-Cotul, Eylem Wrobel, Kinga Zhao, Yiru C Hieronymi, Kadriye Kim, Sung Hoon Katzenellenbogen, Benita Katzenellenbogen, John Madak Erdogan, Zeynep J Endocr Soc Steroid Hormones and Receptors Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver diseases in the United States. Simple and benign steatosis can gradually develop into the more serious conditions of nonalcoholic steatohepatitis (NASH) and cirrhosis. Population studies have demonstrated that men and postmenopausal women have higher incidences of NAFLD compared to premenopausal women, suggesting a protective role for estrogens. The decrease in estrogens due to the onset of menopause make postmenopausal women more susceptible to weight gain, fat redistribution to abdominal areas, dyslipidemia, hypertension and insulin resistance, all of which are major hallmarks of metabolic syndrome and are associated with NAFLD. Pathway preferential estrogen 1 (PaPE-1) is a novel estrogen receptor ligand that has been shown to favorably affect metabolic tissues without stimulating reproductive tissues. Though its effects on weight gain and fat accumulation have been previously investigated, its effects on liver transcriptome and plasma metabolites have yet to be determined. We use transcriptomics and metabolomics analysis to characterize the effects of PaPEs in two different mouse models: diet-induced obesity (DIO) and leptin-deficient (ob/ob) mice. PaPE-1 significantly decreased liver weight and lipid accumulation in both DIO and ob/ob models. Integrated pathway analysis using transcriptomics and metabolomics data showed that PaPE-1 treatment lowered genes associated with inflammation, collagen deposition, and fatty acid metabolism. On the other hand, PaPE-1 significantly increased expression of mitochondrial genes, particularly ones associated with electron transport chain and ribosome synthesis suggesting an increase in energy expenditure and mTOR signaling activity. In addition, PaPE-1 treatment restored insulin sensitivity in hepatocytes. Overall, our data show that PaPE-1 provides a metabolic benefit without stimulation of reproductive tissues. Endocrine Society 2019-04-30 /pmc/articles/PMC6554909/ http://dx.doi.org/10.1210/js.2019-OR09-2 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Steroid Hormones and Receptors
Zuo, Qianying
Arredondo Eve, Alicia
Chen, Karen L
Smith, Brandi
Kulkoyluoglu-Cotul, Eylem
Wrobel, Kinga
Zhao, Yiru C
Hieronymi, Kadriye
Kim, Sung Hoon
Katzenellenbogen, Benita
Katzenellenbogen, John
Madak Erdogan, Zeynep
OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title_full OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title_fullStr OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title_full_unstemmed OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title_short OR09-2 Pathway Preferential Estrogens Prevent Hepatosteatosis Due to Ovariectomy and High-Fat Diets
title_sort or09-2 pathway preferential estrogens prevent hepatosteatosis due to ovariectomy and high-fat diets
topic Steroid Hormones and Receptors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554909/
http://dx.doi.org/10.1210/js.2019-OR09-2
work_keys_str_mv AT zuoqianying or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT arredondoevealicia or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT chenkarenl or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT smithbrandi or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT kulkoyluoglucotuleylem or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT wrobelkinga or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT zhaoyiruc or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT hieronymikadriye or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT kimsunghoon or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT katzenellenbogenbenita or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT katzenellenbogenjohn or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets
AT madakerdoganzeynep or092pathwaypreferentialestrogenspreventhepatosteatosisduetoovariectomyandhighfatdiets